Cargando…

Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial

AIMS: To assess the dose‐related effects of sotagliflozin, a novel dual inhibitor of sodium‐glucose co‐transporters‐1 and ‐2, in type 1 diabetes (T1D). MATERIALS AND METHODS: In this 12‐week, multicentre, randomized, double‐blind, placebo‐controlled dose‐ranging trial, adults with T1D were randomize...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baker, Claire, Wason, Suman, Banks, Phillip, Sawhney, Sangeeta, Chang, Anna, Danne, Thomas, Gesty‐Palmer, Diane, Kushner, Jake A., McGuire, Darren K., Mikell, Frank, O'Neill, Mark, Peters, Anne L., Strumph, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851757/ https://www.ncbi.nlm.nih.gov/pubmed/31264767 http://dx.doi.org/10.1111/dom.13825

Ejemplares similares

Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies
por: Peters, Anne L., et al.
Publicado: (2020)

Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2
por: Rodbard, Helena W, et al.
Publicado: (2021)

The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3
por: Sridhar, Vikas S., et al.
Publicado: (2023)

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption
por: Powell, David R, et al.
Publicado: (2019)

OR22-5 Sotagliflozin Decreases Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption
por: Powell, David, et al.
Publicado: (2019)

Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study
por: Posch, Maximilian G., et al.
Publicado: (2022)

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
por: Sands, Arthur T., et al.
Publicado: (2015)

Validating the Safe and Effective Use of a Neurorehabilitation System (InTandem) to Improve Walking in the Chronic Stroke Population: Usability Study
por: Smayda, Kirsten Elisabeth, et al.
Publicado: (2023)

Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes
por: Danne, Thomas, et al.
Publicado: (2019)

A review of sotagliflozin for use in type 1 diabetes
por: Nuffer, Wesley, et al.
Publicado: (2019)

Lipometabolism and Glycometabolism in Liver Diseases
por: Ding, Hao-ran, et al.
Publicado: (2018)

The journey from gene knockout to clinical medicine: telotristat and sotagliflozin
por: Rendell, Marc S
Publicado: (2019)

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
por: Cefalo, Chiara Maria Assunta, et al.
Publicado: (2019)

Sotagliflozin attenuates cardiac dysfunction and remodeling in myocardial infarction rats
por: Zhong, Peng, et al.
Publicado: (2023)

Sotagliflozin vs Dapagliflozin: A Systematic Review Comparing Cardiovascular Mortality
por: Iyer, Nandhini, et al.
Publicado: (2023)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

How COVID-19 disrupts glycometabolic control
por: Starling, Shimona
Publicado: (2021)

Glycometabolism regulates hepatitis C virus release
por: Yu, Tao, et al.
Publicado: (2021)

Type 2 Diabetic Rats on Diet Supplemented With Chromium Malate Show Improved Glycometabolism, Glycometabolism-Related Enzyme Levels and Lipid Metabolism
por: Feng, Weiwei, et al.
Publicado: (2015)

Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes
por: Powell, David R, et al.
Publicado: (2015)

Irisin regulates the expression of BDNF and glycometabolism in diabetic rats
por: Huang, Lingning, et al.
Publicado: (2019)

Advances of Glycometabolism Engineering in Chinese Hamster Ovary Cells
por: Zhang, Huan-Yu, et al.
Publicado: (2021)

The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes
por: van Raalte, Daniël H., et al.
Publicado: (2019)

Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
por: Koufakis, Theocharis, et al.
Publicado: (2021)

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects
por: He, Xuemei, et al.
Publicado: (2022)

Caveolin-3 promotes glycometabolism, growth and proliferation in muscle cells
por: Shang, Lina, et al.
Publicado: (2017)

Erectile Dysfunction Severity: The Role of Glycometabolic Compensation and Antihyperglycemic Drugs
por: Zamponi, Virginia, et al.
Publicado: (2022)

Effects of chromium malate on glycometabolism, glycometabolism-related enzyme levels and lipid metabolism in type 2 diabetic rats: A dose–response and curative effects study
por: Feng, Weiwei, et al.
Publicado: (2015)

Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction
por: Kim, Inho, et al.
Publicado: (2023)

Correction: Caveolin-3 promotes glycometabolism, growth and proliferation in muscle cells
Publicado: (2018)

Oxidative Stress and Left Ventricular Performance in Patients with Different Glycometabolic Phenotypes
por: Cassano, Velia, et al.
Publicado: (2022)

Vascular Damage and Glycometabolic Control in Older Patients with Type 2 Diabetes
por: Karasek, David, et al.
Publicado: (2023)

Autophagy and Glycometabolic Reprograming in the Malignant Progression of Lung Cancer: A Review
por: Li, Yuting, et al.
Publicado: (2023)

Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: A systematic review and meta-analysis
por: Chen, Mao-Bing, et al.
Publicado: (2020)

The safety of sotagliflozin in the therapy of diabetes mellitus type 1 and type 2: A meta-analysis of randomized trials
por: Zhou, Feifei, et al.
Publicado: (2022)

Role of AMPKα in Skeletal Muscle Glycometabolism Regulation and Adaptation in relation to Sepsis
por: Zheng, Xia, et al.
Publicado: (2014)

Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life
por: Mongioì, L M, et al.
Publicado: (2017)

Effects of Acute Cold Stress on Liver O-GlcNAcylation and Glycometabolism in Mice
por: Yao, Ruizhi, et al.
Publicado: (2018)

Glycometabolic rearrangements--aerobic glycolysis in pancreatic cancer: causes, characteristics and clinical applications
por: Cao, Lidong, et al.
Publicado: (2020)

Vitamin D Deficiency Is Associated with Glycometabolic Changes in Nondiabetic Patients with Arterial Hypertension
por: Brosolo, Gabriele, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9mmock135ol58h0qe875gh01p2